Shanghai Henlius Biotech's (HKG:2696) serplulimab injection in combination with carboplatin and etoposide has been approved by the European Commission for the first-line treatment of adult patients with extensive-stage small cell lung cancer, a Wednesday bourse filing said.
The injection is an anti-PD-1 monoclonal antibody used for the treatment of various types of lung cancer. It has been approved in mainland China to be used in combination with chemotherapy.
The injection will be deployed in Europe under the trade name Hetronifly. The approval implies a centralized marketing authorization for the injection for all the EU member states together with Iceland, Liechtenstein, and Norway.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。